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Objective: To evaluate subclinical atherosclerosis in Behcet disease (BD), we performed a systematic review
and meta-analysis of studies where atherosclerosis was determined by ﬂow-mediated dilatation (FMD) and
endothelial-mediated dilatation (EMD) and by measurement of intima media thickness (IMT) of carotid
arteries.
Methods: Systematic search of EMBASE and PubMed databases from January 2000 to January 2014 according
to PRISMA guidelines.
Results: Nine studies met the inclusion criteria on FMD/EMD,11 on IMT and 4 on both. BD had lower FMD than
controls (SMD ¼ 0.89, 95% CI: 0.660 to 1.11, p o 0.001), which was conﬁrmed by subgroup analyses
on active and inactive patients (SMD ¼ 1.17, 95% CI: 1.45 to 0.89 and SMD ¼ 0.72, 95% CI: 0.97
to 0.46, p ¼ 0.0001 for both). EMD was lower in BD but with a large estimate (SMD ¼ 0.38, 95% CI: 0.79
to 0.03, p ¼ 0.06, I2 ¼ 82.2%). IMT was greater in BD and the large estimate (SMD ¼ 0.95, 95% CI: 0.63–1.28,
p o 0.0001, I2 ¼ 87.6%) persisted after subgroup analysis on active and inactive patients (I2 ¼ 88.4% and 86.7%,
respectively). Pooling IMT studies by a Newcastle Ottawa Scale of 5 and 6/7 yielded lower estimates (SMD ¼
0.54, 95% CI: 0.32–0.75, p o 0.0001, I2 ¼ 58.7% and SMD ¼ 1.72, 95% CI: 1.35–2.09 p o 0.05, I2 ¼ 48.6%).
Conclusions: FMD is impaired in BD even in inactive state and IMT is greater despite a degree of statistical
heterogeneity that reﬂects the clinical heterogeneity of BD. Future prospective studies should account for risk
stratiﬁcation of atherosclerosis in BD.
& 2015 The Authors. Published by Elsevier HS Journals, Inc. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Behcet’s disease (BD) is a systemic vasculitis characterised by
recurrent oral and genital aphthosis, ophthalmic, cutaneous, artic-
ular, intestinal, urogenital, neurological, pulmonary and vascular
manifestations [1]. The prevalence of vascular involvement may be
as high as 40% according to the ethnicity of the population under
study [2] and superﬁcial thrombophlebitis accompanies vascular
occlusion in almost 13% of patients [3]. The vascular manifesta-
tions are prevalently venous thrombosis as well as aneurysm
formation; occlusions in the superior and inferior vena cava, inr HS Journals, Inc. This is an open
, endothelial-mediated dila-
le Ottawa Quality Assessment
s.com, an Italian Registered
bosis Centre, Royal Inﬁrmary
A, Scotland, UK.the supra-hepatic vein and in the cerebral vein range between 3%
and 41% [4]; aneurysms commonly develop in the pulmonary
arteries but do not spare femoral, popliteal, subclavian and
common carotid arteries [2]. Arterial disease ranges from 0.5% to
17% [2] and though the prevalence of myocardial is only 1.1%, it
occurs in relatively young BD patients in their third decade of life
[5] and may be silent in up to 25% of cases [6]. The standardized
mortality ratio calculated from 428 BD patients was 10-fold higher
than the reference population in the age group of 14–24 years,
with pulmonary artery aneurysms and Budd–Chiari syndrome the
leading cause of death followed by arterial disease, though the
standardized mortality ratio decreased in older age groups [7].
Given the chronic inﬂammatory background of BD, the issue of
premature atherosclerosis was addressed over the last decades
with conﬂicting evidence [8]. We therefore assessed the available
data by performing a systematic review and a meta-analysis of the
studies where atherosclerosis was assessed by ﬂow-mediated
vasodilation (FMD) and endothelial-mediated vasodilation (EMD)
and by measurement of the intima media thickness (IMT) of
carotid arteries, noninvasive markers of endothelial health inaccess article under the CC BY-NC-ND license
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FMD/EMD measured at the brachial artery and IMT measured at
the carotid arteries derived from studies comparing BD patients
with groups of individuals deemed as healthy controls.Methods
Search strategy and selection criteria
A systematic review according to the PRISMA guidelines was
carried out [11]; the PubMed and EMBASE databases were searched
with the following terms: BD, atherosclerosis, ﬂow-mediated vaso-
dilatation and endothelial dysfunction, intima media thickness and
carotid. A preliminary search had not revealed any articles on the
topic before January 2000 therefore, the ﬁnal search spanned from
January 2000 up to January 2014. Review articles, case reports and
surveys on aneurysms regardless of the vascular districts were
excluded. The reference list of retrieved papers was checked for
references that could have been missed.
Criteria for selecting articles
Two investigators (M.M. and P.R.J.A.) independently assessed all
the papers generated for relevancy and considered those observa-
tional case–control studies addressing the difference in mean
brachial artery FMD and EMD and mean carotid artery IMT
between BD patients and matched healthy controls. To be included
in the review, the articles had to meet the following criteria: (1) BD
patients and matched healthy controls had to be compared for
FMD/EMD at the brachial artery and IMT at the common carotid
artery and (2) the technique for brachial artery and carotid artery
IMT measurement had to be based on similar published protocols
[9,10]. Exclusion criteria were the following: (1) articles not
written in English, (2) studies not comparing BD patients with
healthy controls and (3) measurement of IMT of carotid arteries
and of brachial artery FMD/EMD that deviated substantially from
predeﬁned protocols [9,10]. M.M. and P.R.J.A. screened all abstracts
and applied the eligibility criteria in order to identify studies that
were appropriate for inclusion. They independently extracted data
using predeﬁned criteria, which included date of publication,
population, language, study design, participant data and results.
Evaluation of the quality of the studies
The quality of the studies identiﬁed was assessed by the
Newcastle Ottawa Quality Assessment Scale (NOQAS) for
case–control studies speciﬁcally developed to assess quality of
observational studies; however, all the studies evaluated and
included in the meta-analysis are simply comparing two different
groups because they had no real exposure to qualify as true case–
control [12]. The scoring system covers three major domains
(selection of cases and controls, comparability of selected groups
and ascertainment of either the exposure or outcome of interest)
and the resulting score may range between 0 and 8, a higher score
representing a better methodological quality. Data were independ-
ently extracted into a standard electronic form and averaged and
any discrepancies were resolved by consensus.
Outcome measures
The primary outcomes were the mean differences of FMD/EMD
measured at the brachial artery and of IMT measured at the
common carotid arteries. Data on mean values in both BD patients
and matched healthy groups were collected to investigate the
extent to which a pooled standardized mean difference betweengroups can be derived and considered as representative for BD
patients. The secondary outcome was the difference of the pooled
prevalence of subjects with carotid plaques derived from the BD
and the healthy group.
Statistical analysis
Statistical analysis was carried out using STATA (StataCorp. 2013;
Stata Statistical Software: Release 13; College Station, TX: StataCorp
LP). Random effects meta-analyses for continuous outcomes (FMD,
EMD and IMT) were employed as the estimates were the result of
observational studies rather than planned experiments such as clinical
trials. Besides clinical rich information, each study contained informa-
tion on outcomes means, standard deviations and number of individ-
uals in each group. The aim of the analysis was to investigate the
average effect of the outcomes attributable to BD group; that is a
standardized mean difference between BD patients and normal
healthy individuals. Statistical heterogeneity among studies was
assessed with chi square Cochran’s Q test and with I2 statistics, which
measures the inconsistency across study results and describes the
proportion of total variation in study estimates that are due to
heterogeneity rather than sampling error. More speciﬁcally, an I2 value
of 0% indicates absence of heterogeneity and values less than 25%
indicate low, between 25% and 50% moderate and over 50% high
heterogeneity [13]. Subgroup analyses were based on clinical judg-
ment, similarity of circumstances in which the studies have been
conducted and the publication index. Whilst empirical methods such
as Funnel plots [14,15] were part of preliminary investigations, the
ﬁnal estimates for an average effect on the BD outcomes relied on
robust clinical and statistical compatibility, i.e., with evidence consis-
tent with studies homogeneity [16]. Peto’s method for pooled odds
ratios was used to compare subjects with carotid artery plaques within
BD and control groups because of its good performance when events
are very rare [17].Results
After completion of the screening process (Fig. 1), 24 studies met
the criteria for inclusion in the analysis: 9 investigated FMD and/or
EMD [18–26], 11 IMT [8,27–36] and 4 investigated both [37–40].
Quality of the studies
A score of Z7 on the NOQAS was arbitrarily taken as a threshold
for a good quality study: in the FMD/EMD section four studies
ranked at Z7 [19,21,23,26] (Table 1). In the IMT section part of the
study only one study achieved a high score [8] (Table 2). Reasons for
achieving a low score were poor selection criteria, poor documen-
tation of patient and/or control inclusion/exclusion criteria,
inadequate matching, poor comparability and failure to report
disease duration and/or disease activity. The inter-rater reliability
agreement of the two investigators (M.A. and P.R.J.A.) for NOQAS
was 0.41 (95% CI: 0.0836–0.745) calculated by Cohen’s kappa.
Analysis of ﬂow-mediated vasodilatation
Data from 13 case–control studies comprising 554 patients with BD
and 472 controls were pooled for the effect size of this outcome
(Table 1). Random effect meta-analysis revealed wide heterogeneity
amongst the studies (I2¼95.6%, p o 0.0001) suggesting poor pros-
pects for average pooled estimates. Having explored the causes for this
heterogeneity, four studies [18,19,21,24] deviated slightly from the
FMD methodology in that the cuff of the sphygmomanometer was
applied at the forearm, a technique that yields a lower value than
applying the cuff at the upper arm [41]. Removal of the four studies
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Fig. 1. Summary of literature search according to the Prisma ﬂow chart. Full text excluded n ¼ 6 investigated pulse wave velocity, n ¼ 3 investigated coronary artery disease,
n ¼ 1 did not provide intima media thickness measurements, n ¼ 2 repeated study on same patients in same year and n ¼ 1 had no control group.
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CI: 1.11 to 0.66, p ¼ 0.0001, I2 ¼ 45.3%) (Fig. 2A).
BD patients were then split according to active and inactive disease
where possible: we arbitrarily considered patients with vascular
involvement [20,37,38] as having active disease and pooled themwith
active disease patients proper [20,22,23,25,26,40]: FMD was signiﬁ-
cantly lower with moderate heterogeneity (SMD ¼ 1.17, 95%
CI: 1.45 to 0.89, p ¼ 0.0001, I2 ¼ 37.5%) (Fig. 2B). Pooled data
from inactive disease patients [20,22,23,25,26,37–39] also revealed
impaired FMD with moderate heterogeneity (SMD ¼ 0.74, 95% CI:
0.97 to 0.51, p ¼ 0.0001, I2 ¼ 35.5%) (Fig. 2C).
Analysis of endothelial-mediated vasodilatation
Of the 13 case–control studies evaluating FMD, eight also
evaluated EMD (Table 1). Data of these eight case–control studies
comprising 360 BD patients and 306 controls were pooled for this
outcome. Random effect meta-analysis showed some evidence
for impaired EMD in BD (SMD ¼ 0.380, 95% CI: 0.027 to 0.788,
p ¼ 0.06) but with elevated heterogeneity (I2 ¼ 82.2%).
Analysis of intima media thickness of carotid arteries
Data from 15 case–control studies comprising 848 patients with
BD and 677 controls were pooled for the effect size of this outcome(Table 2). Random effect meta-analysis revealed wide heterogeneity
(I2 ¼ 87.6%, p o 0.0001 for both) invalidating the pooled estimate
(Fig. 3A). All investigators measured IMT at the common carotid
artery but for one study where the authors presented the average
IMT taken at the distal common carotids, at the far wall of the
carotid bulbs and at the far wall of the internal carotid artery [8].
Indeed studies varied with regards to inclusion criteria: n ¼ 3
compared patients with and without vascular involvement and
provided separate measurements [27,37,38], n ¼ 1 provided sepa-
rate data for patients with and without systemic involvement
(mucocutaneous only) [36], n ¼ 3 studies included a mixture of
active and inactive disease [32,34,40] of which one provided
separate data for active and inactive disease [32], n ¼ 3 studies
were carried out on patients with low or inactive disease [31,33,35],
n ¼ 2 were carried out on patients without vascular and/or systemic
involvement [38,39] and n ¼ 2 were carried out in patients without
cardiovascular risk factors [28,30].
To reduce heterogeneity, we arbitrarily aligned patients accord-
ing to (1) inactive disease, (2) no vascular involvement and (3) no
systemic involvement. We therefore extracted data of patients
without vascular involvement from the three studies where these
data were provided separately [27,37,38], we extracted the data of
the patients without systemic involvement [36], we maintained
the data of the patients with inactive disease [32] and we excluded
the only study where inactive and active disease patients could not
Table 1
Demographics, ﬂow and endothelial-mediated vasodilatation and Newcastle Ottawa Scale for controls and Behcet's disease
Study Controls Behcet's Disease NOS
N M/F Age FMD EMD N M/F Age Disease status FMD EMD
Ozuguz et al. [26] 20 8/12 37 7 10.3 14.3 7 5.52 40 15/25 39.6 7 9.9 AD/ID 9.4 7 3.5 7
Yurdakul et al. [39] 20 12/8 45.4 7 8.2 16.36 7 4.62 20.05 7 1.57 40 24/16 44.9 7 5.4 Non vasc/non S 13.34 7 4.92 16.31 7 2.45 6
Yuksekkaya et al. [25] 25 15/10 35 7 10 26 7 18 30 16/14 39 7 12 AD/ID 10.83 7 12.62 5
Can et al. [40] 51 23/28 34.5 7 7.2 9.04 7 4.8 36 14/22 39.6 7 6.4 AD/ID 5.2 7 3.8 5
Acigoz et al. [24] 40 22/18 35.2 7 9.8 15.5 7 1.6 18.1 7 1.3 40 24/16 34.7 7 8.6 AD 5.2 7 1.4 17.7 7 1.3 6
Caliskan et al. [38] 35 19/16 38.1 7 7.9 18.5 7 8 53 24/29 36.75 7 6.35 VD/non V 16.4 7 8.05 4
Ulusoy et al. [23] 29 24/5 29.5 7 5.8 21.4 7 6.4 19.2 7 5.3 28 24/4 31.1 7 7.1 MC 15.7 7 2.4 18.4 7 6.2 7
Caliskan et al. [22] 35 35.9 7 4.6 15.83 7 5.29 35 36.5 7 6.8 AD/ID 11.21 7 7.96 6
Protogerou et al. [21] 90 58/32 40.1 7 1.2 5.7 7 0.4 13.4 7 0.7 87 29/58 39.5 7 2.7 AD/ID 4.1 7 0.4 12.8 7 0.5 7
Kayikcioglu et al. [20] 30 18/12 41 7 8 20.4 7 9.1 25.3 7 10.5 65 40/25 38 7 9 ID/V/non V 11.4 7 6.3 21.6 7 20.5 6
Oﬂaz et al. [37] 46 37/9 36.2 7 9.3 14.41 7 3.39 17.82 7 5.27 50 41/9 38.7 7 9.3 V/non V 10.41 7 3.85 18.8 7 6.06 6
Ozdemir et al. [19] 30 20/10 36 7 8 4.4 7 3.4 16.1 7 3.9 31 19/12 37 7 7 ID/no CVD 1.4 7 3 16.4 7 3.7 7
Chambers et al. [18] 21 10/11 40 7 2 5.7 7 0.9 19.7 7 1.9 19 9/10 41 7 2 AD 0.7 7 0.9 19.7 7 1.7 6
N: numbers; M/F: male/female; AD: active disease; ID: inactive disease; V: vascular; CVD: cardiovascular risk disease.
Table 2
Demographics, intima media thickness and Newcastle Ottawa Scale for controls and Bechet’s disease patients
Study Country Controls Behcet’s disease
N M/F Age IMT Pl% N M/F Age Disease status IMT Pl % Dis Dur NOS
Caldas et al. [36] Brasil 23 11/12 35.4 7 6 0.561 7 0.134 NM 23 11/12 35 7 7.6 Sys/MC 0.594 7 0.138 NM 8.9 7 5.6 6
Can et al. [40] Turkey 51 23/28 34.5 7 7.2 0.39 7 0.09 NM 36 14/22 39.6 7 6.4 AD/ID 0.56 7 0.122 NM 4
Hassan et al. [35] Egypt 20 NA 34.5 7 4.2 0.4 7 0.1 0 30 25/5 35.8 7 8.7 ID 0.72 7 0.4 16.7 8.7 7 5.9 5
Yurdakul et al. [39] Turkey 20 12/8 45.4 7 8.2 0.59 7 0.09 NM 40 24/16 44.9 7 5.4 Non sys/non V 0.69 7 0.15 NM 5.9 6
Ozgen et al. [34] Turkey 29 6/23 38 7 10 0.547 7 0.04 NM 37 18/19 35.3 7 10 AD/ID 0.675 7 0.07 NM 3.9 7 4.7 5
Messedi et al. [33] Tunisia 50 35/15 46 7 7 0.581 7 0.087 2 50 35/15 48 7 6 ID 0.658 7 0.112 10 12.8 7 8.7 6
Hong et al. [32] Korea 20 13/7 40.2 7 5.1 0.59 7 0.11 0 40 24/16 39.1 7 8.5 AD/ID 0.71 7 0.17 2.5 5.2 7 4 6
Caliskan et al. [38] Turkey 35 19/16 38.1 7 7.9 0.46 7 0.82 NM 53 24/29 36.75 7 6.35 V/non V 0.515 7 0.012 NM 4.08 7 4.5 4
Ozturk et al. [31] Turkey 21 15/6 35 7 8 0.57 7 0.14 NM 21 15/6 35.8 7 8.6 ID 0.86 7 0.18 NM 7.3 7 5.8 5
Seyahi et al. [8] Turkey 156 83/73 39 7 6.6 0.68 7 0.08 15.38 239 162/27 40 7 6.6 0.71 7 0.09 26.36 12 7
Rhee et al. [30] Korea 53 26/27 37.1 7 7.2 0.52 7 0.06 0 41 20/21 37.6 7 7.9 No CVD risk 0.52 7 0.09 0 6.5 7 0.6 6
Ozturk et al. [29] Turkey 34 21/13 34.6 7 8.5 0.54 7 0.13 0 34 21/13 34.6 7 8.5 Non V 0.81 7 0.17 17.6 7 7 5.2 5
Oﬂaz et al. [37] Turkey 46 37/9 36.2 7 9.3 0.55 7 0.14 NM 50 41/9 38.7 7 9.3 V/non V 0.69 7 0.15 NM 6
Keser et al. [28] Turkey 77 46/31 37.2 7 7.8 0.48 7 0.09 0 114 68/46 38.1 7 9.4 No CVD risk 0.55 7 0.14 4.38 10.08 7 6.58 6
Alan et al. [27] Turkey 42 25/17 40 7 9 0.59 7 0.12 5 40 19/21 39.8 7 8 V/non V 0.81 7 0.12 10 5
N: numbers; M/F: male/female; IMT: intima media thickness carotid; Pl%: plaque percentage; Dis Dur: disease duration; NOS: Newcastle Ottawa Scale; NA: not available; AD: active disease; ID: inactive disease; V: vascular;
CVD: cardiovascular risk disease; NM: not mentioned.
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Fig. 2. Forest plots of ﬂow-mediated dilation (FMD) on (A) all studies, (B) on inactive Behcet's disease and (C) on active Behcet's disease.
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remaining studies. The random effect meta-analysis showed sig-
niﬁcant heterogeneity (I2 ¼ 80.1%, p o 0.0001). Therefore, weanalysed separately patients with no vascular involvement and no
cardiovascular risk factors [27–30,37–40] and still attained wide
heterogeneity (I2 ¼ 82%, p o 0.0001).
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Fig. 3. Forest plots of the intima media thickness (IMT) of carotid arteries on (A) all studies, (B) on studies with a NOQAS of 5 and (C) on studies with a NOQAS of 6/7.
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pooled patients according to (1) active disease, (2) vascular
involvement and (3) systemic involvement. We extracted datafrom patients with systemic involvement [36] and with vascular
disease [27,37,38] on the assumption they implied active disease,
we removed two studies with a mixture of active and inactive
M. Merashli et al. / Seminars in Arthritis and Rheumatism 45 (2016) 502–510508patients [34,40] and repeated the random effect analysis that
yielded again wide heterogeneity (I2 ¼ 86.8%).
We ﬁnally re-approached the meta-analysis according to the
NOQAS: pooled data from studies with a NOQAS of 5 revealed
larger IMT in BD patients than controls (SMD ¼ 0.54, 95% CI: 0.32–
0.75, p o 0.0001) with moderate to high heterogeneity
(I2 ¼ 58.7%) (Fig. 3B) and pooled data from studies with a NOQAS
of 6/7 also revealed moderate heterogeneity (I2 ¼ 58.7)(Fig. 3C).Analysis of carotid plaque frequency
The presence of carotid plaques was investigated in eight
studies [8,27–30,32,33,35] but we pooled only 7 case–control
studies comprising 547 BD patients and 397 controls for the effect
size of this outcome because one study had found plaques neither
in BD subjects nor in controls [30]. The pooled prevalence of
subjects with carotid plaques was 12% in the BD population (range
from 4% to 18%) and 3.7% (range from 2% to 9%) in the control
group. Peto’s meta-analysis revealed an OR of 2.853 (95% CI: 1.814–
4.487; p ¼ 0.0001) with no heterogeneity (I2 ¼ 4.18) (Fig. 4),
indicative of a strong prevalence of patients with plaques in the BD
populations under consideration.Discussion
This meta-analysis shows that FMD is impaired in BD patients:
in keeping with the possibility that incident disease activity would
have a major impact on FMD at the time of the endothelial
investigations we found a greater degree of FMD impairment in
patients with higher disease activity; however, FMD impairment
during inactive disease means that BD patients are at risk of
arterial damage in the long term. Some of the FMD studies also
assessed EMD but the apparent difference between BD and
controls was offset by wide statistical heterogeneity. While EMD
depends on exogenous nitric oxide for the relaxation of smooth
muscle cells within the vasculature, FMD relies mostly on the
biological activity of endogenous nitric oxide which may be
impaired both in relation to disease activity [42] and to typeOverall  (I-squared = 0.0%, p = 0.653)
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Fig. 4. Individual study contribution to the pooled odds ratio fovascular involvement [43] in BD and shows age and sex depend-
ency [44].
In an “inﬂammatory vascular disease” such as Behcet’s [1], the
endothelium may be acutely affected in active disease and chroni-
cally affected in apparently inactive disease eventually contribu-
ting to atherosclerosis: in cross-sectional studies incident disease
status, and drug intake may have more immediate impact on
functional measurements such as FMD/EMD than a more “static”
measurement such as IMT. Several inﬂammatory, immunological
and metabolic factors may contribute to early FMD dysfunction in
BD: elevated plasma concentration of homocysteine [19,26] C-
reactive protein [22,26], enhanced oxidative [24] and nitrative
stress [45], impaired biological activity of nitric oxide [42,43] and
an abnormal lipid proﬁle [19,22,43]. However, because these data
were not uniformly present in the studies included in the meta-
analysis we could not perform a meta-regression that would have
explained to what extent the abovementioned factors contributed
to the FMD difference between BD and controls.
Nevertheless, given the independent predictive value of
impaired FMD on cardiovascular risk [46] most of the BD patients
in this meta-analysis were diseased long enough to have accrued
arterial wall damage expressed as a greater IMT and or as plaque.
In fact our meta-analysis revealed overall thicker intima media in
BD patients in keeping with the atherosclerosis hypothesis though
pooled data from all studies revealed high statistical heterogeneity.
We were not surprised of this result as we know that BD is a very
heterogeneous disease in itself. On the other hand, the data we
obtained on the prevalence of BD patients with plaques were
devoid of heterogeneity and very convincing in terms of signiﬁ-
cance. The studies included in this part of the meta-analysis were
carried out on small cohorts of BD patients that varied according to
disease activity, presence or absence of systemic disease, of
vascular involvement and of cardiovascular risk factors. Moreover,
BD patients were on different pharmacological treatments for
varied lengths of time and the gender difference so relevant in
atherosclerosis was poorly accounted for but in one large study
where IMT was unaffected by sex [8].
Additionally, some sociocultural atherosclerotic risk factors
such as diet and physical activity can vary according to different
geographical regions, though most of the studies of this meta-2.85 (1.81, 4.49)
(Excluded)
2.04 (0.39, 10.65)
2.17 (1.23, 3.81)
4.48 (0.07, 286.49)
8.68 (1.64, 45.83)
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6.14 (0.95, 39.72)
OR (95% CI)
5.54 (0.91, 33.70)
100.00
0.00
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%
Weight
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nalysis using Peto's method
r the presence of plaque in patients with Behcet’s disease.
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Interestingly, however, when the meta-analysis was re-run on the
same studies pooled by the NOQAS there was less variance than
pooling by subgroups of disease activity: this suggests that quality,
reﬂected also in the small size of the studies that inherit large
variability, represents a major determinant of our IMT meta-
analysis. Nevertheless, we present robust statistics based on
clinically compatible and comparable papers that rule against the
possibility of publication bias evaluated by an often misleading
empirical graphical method; on the other hand, the results may
suffer from aggregation bias because the analysis was not based on
the individual data of the participants [47]. The risk of venous
thrombosis is 14-fold higher and that of arterial thrombosis 5.4-
fold higher in BD [48]: immune suppression decreases the risk of
recurrent venous occlusion by a hazard ratio of 0.27 [49] and the
annual incidence of arterial disease by almost fourfold [50], though
the presence of venous and arterial involvement is negatively
associated with complete remission [50].
In the general population, there is some evidence that subjects
who suffer idiopathic venous thrombosis have a 60% higher risk of
developing atherosclerotic disease [51], conﬁrmed by a cohort
study from Denmark where a 20–40% risk persisted 20 years after
the thrombotic event [52]. The patients in these studies are at least
a decade older than the BD patients of our meta-analysis, and
although not all of the BD patients in our meta-analysis suffered
venous thrombosis, the issue of atherosclerosis in BD should be
evaluated also in older BD populations.Conclusion
Atherosclerosis expressed as impaired FMD, greater IMT and
plaque frequency represents a clinical feature of BD in their fourth
decade; however, as cross-sectional studies cannot prove causality,
future studies should be adequately powered and prospectively
designed with serial FMD and carotid ultrasound measurements to
understand which subgroups of BD patients are at greater risk of
developing atherosclerosis and deﬁne whether they should receive
risk factor modiﬁcations and/or preventative measures at an early
stage of endothelial dysfunction to retard the development of
additional cardiovascular disease.References
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